Development of an ELISA for detection of mitragynine and its metabolites in human urine
Graphical abstract
Introduction
Mitragyna speciosa is an herbal plant indigenous to Southeast Asian countries, such as Thailand, Malaysia and Myanmar [[1], [2], [3]]. It is a member of the Rubiaceae family which is the same as the coffee tree [4]. The plant is known by various names such as ‘Kratom’ in Thailand; ‘biak-biak’ and ‘ketum’ in Malaysia [2,5,6]. This traditional medicinal plant is used by local communities to treat human diseases including fever, cough, diarrhea, hypertension, counter fatigue, relieve pain, and diabetes mellitus [3,5,7,8]. It is also used to prevent withdrawal symptoms in opiate-dependent individuals and as a substitute for opium [5,9,10]. The leaves are consumed by chewing, brewing, and smoking [11]. Effects appear within 5–20 min and last for 60–90 min depending on the amount consumed [5].
More than 40 alkaloids have been isolated from Kratom. Mitragynine is the major alkaloid (up to 66% of the total alkaloid extract) in Kratom [12]. The methoxy group at position C9 is the key for pharmacophore binding to opioid receptors which controls the intrinsic activities on opioid receptors [13]. 7α-Hydroxy-7H-mitragynine accounts for 2% of the total alkaloid extract. Although it is present in a minor amount, it is 46-fold more potent as an analgesic compared to mitragynine [14]. 7α-Hydroxy-7H-mitragynine is a potential candidate for pain management as an opioid alternative. It is believed to be the most pharmacologically active alkaloid from Mitragyna speciosa.
Nelsen et al. [15] reported a case of seizure and coma. The patient had a medical history of managing chronic pain and depression with amitriptyline, oxycodone, and Kratom. A death involving abuse of propylhexedrine and mitragynine was reported by Holler et al. [16]. From 2009 to 2010, nine fatal cases of intoxication associated with the use of ‘Krypton’ – a blend containing Kratom and O-desmethyltramadol were reported in Sweden [17]. Furthermore, Neerman et al. [18] reported a fatal case possibly related to Kratom toxicity in United States. According to Domingo et al. [19], there were 2 cases of fatalities reported which confirmed the use of Kratom. The results showed mitragynine was not the primary cause of death in both cases reported. Olsen et al. [20] reported 152 Kratom-positive fatalities during July 2016–December 2017 in United States. Among the 152 Kratom-positive decedents, Kratom was determined to be a cause of death although the presence of additional substances cannot be ruled out.
Using Kratom regularly can have many long-term effects. Kratom users can experience dryness of mouth, darkening of the skin, stomach distension, withdrawal syndrome, sweating, itching, nausea, loss of appetite, anorexia, weight loss, insomnia, constipation, and increase urination [10,11,21,22]. According to Chan et al. [21], this plant has been prohibited by Thai law since 1943 due to its narcotic-like effects. It is also controlled in other countries like Malaysia, Myanmar, Australia, Vietnam, and Denmark [7]. However, it is uncontrolled in Europe and the United States and it is widely available through the internet [10]. Cases of Kratom abuse in Malaysia have raised significant concerns among the public and Law enforcement authorities. Therefore, the Malaysia government is in the final process of scheduling Kratom under the Dangerous Drug Act 1952 in order to strengthen control of Kratom misuse [23].
Detection of mitragynine in biological fluids is necessary to monitor Kratom abusers. Immunoassays are traditionally useful methods for the rapid detection of drugs of abuse as they are cheap, fast, easy, and sample pre-treatment is not necessary [24]. Limsuwanchote et al. [25] have reported the production of monoclonal antibody against mitragynine for quantification of mitragynine in Kratom samples using an indirect competitive Enzyme-linked Immunosorbent assay (ELISA). Currently, there is no study reported using polyclonal antibody. Polyclonal antibody has the ability to detect multiple epitopes and gives more robust detection as well as offer greater sensitivity for detection. This paper describes the preparation of mitragynine-protein conjugate, enzyme conjugate and the generation of polyclonal antibodies against mitragynine. The antibodies are characterized by cross-reactivity study. Competitive inhibition ELISA for the detection of mitragynine, other closely related Kratom alkaloids and metabolites in human urine are described.
Section snippets
Reagents and standards
Bovine serum albumin (BSA) in lyophilized form, complete and incomplete Freund's adjuvants, sodium acetate anhydrous, anti-rabbit IgG, Tween® 20, ProClin® 300, ethylenediamine dihydrochloride (EDA.2HCl), formaldehyde, trifluoroacetic acid, sinapinic acid, hexane, ammonium formate, formic acid, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC), protein A from Staphylococcus Aureus, acetonitrile, caffeine, and methadone were purchased from Sigma Aldrich Corporation, St. Louis,
Preparation of antibody
Mitragynine is not sufficiently immunogenic to induce antibody production because of low molecular mass, therefore it has to be conjugated to a carrier protein, which has high molecular mass and immunogenic to elicit an immune response when introduced into animals. Both the cBSA-MG and HRP-MG conjugates were synthesized using the same approach - Mannich reaction. In the Mannich reaction, mitragynine was coupled through the indole nitrogen via formaldehyde treatment with sodium acetate to cBSA.
Conclusions
A sensitive ELISA assay has been developed to screen the presence of mitragynine in urine samples. This is a useful method for rapid screening of biological samples where no sample preparation is required. The antibodies produced were specific against mitragynine and metabolites as well as other closely related Kratom alkaloids. The results obtained were confirmed using LC-MS/MS method which proved the reliability and sensitivity of the ELISA assay. The future study is to investigate the
Ethical approval
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
CRediT authorship contribution statement
Mei Jin Lee: Methodology, Investigation, Writing - original draft, Writing - review & editing, Funding acquisition. Surash Ramanathan: Conceptualization, Investigation, Writing - review & editing, Resources, Supervision. Sharif Mahsufi Mansor: Investigation, Resources. Soo Choon Tan: Conceptualization, Methodology, Writing - original draft, Funding acquisition, Supervision.
Declaration of competing interest
There are no financial or other relations that could lead to a conflict of interest.
Acknowledgements
This study was funded by the Higher Institution Centre of Excellence, HICoE (grant number 311.CIPPM:4401005, 311/CDADAH/4401009) which provided by Ministry of Higher Education (MOHE), Malaysia; and the Ministry of Education (Malaysia) MYBRAIN15 scholarship.
References (35)
- et al.
Antinociceptive action of mitragynine in mice: evidence for the involvement of supraspinal opioid receptors
Life Sci.
(1996) - et al.
New indole alkaloids from the leaves of Malaysian Mitragyna speciosa
Tetrahedron
(1998) - et al.
Inhibitory effect of mitragynine, an alkaloid with analgesic effect from Thai medicinal plant Mitragyna speciosa, on an electrically stimulated contraction of isolated Guinea-pig ileum through the opioid receptor
Life Sci.
(1997) - et al.
Factors influencing the release of Mitragyna speciosa crude extracts from biodegradable P (3HB-co-4HB)
Int. J. Pharm.
(2008) - et al.
Alkaloids from Mitragyna speciosa
Phytochemistry
(1991) - et al.
Opioid receptor agonistic characteristics of mitragynine pseudoindoxyl in comparison with mitragynine derived from Thai medicinal plant Mitragyna speciosa
Gen. Pharmacol.
(1999) - et al.
Inhibitory effects of Kratom leaf extract (Mitragyna speciosa Korth.) on the rat gastrointestinal tract
J. Ethnopharmacol.
(2008) - et al.
Mitragynine inhibits the COX-2 mRNA expression and prostaglandin E (2) production induced by lipopolysaccharide in RAW264.7 macrophage cells
J. Ethnopharmacol.
(2011) - et al.
Suppressive effect of mitragynine on the 5-methoxy-N, N-dimethyltryptamine-induced head-twitch response in mice
Pharmacol. Biochem. Behav.
(1997) - et al.
Antinociceptive effect of 7-hydroxymitragynine in mice: discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa
Life Sci.
(2004)
Mitragynine concentrations in two fatalities
Forensic Sci. Int.
Acute and long-term effects of alkaloid extract of Mitragyna speciosa on food and water intake and body weight in rats
Fitoterapia
Immunoassay
Curr. Opin. Biotechnol.
Development of indirect competitive ELISA for quantification of mitragynine in Kratom (Mitragyna speciosa (Roxb.) Korth.)
Forensic Sci. Int.
Method validation in quantitative analysis of phase I and phase II metabolites of mitragynine in human urine using liquid chromatography-tandem mass spectrometry
Anal. Biochem.
Radioimmunoassay for reserpine
Life Sci.
Melamine and cyanuric acid do not interfere with Bradford and Ninhydrin assays for protein determination
Food Chem.
Cited by (4)
Sensitive detection of mitragynine from Mitragyna speciosa Korth using an electrochemical immunosensor based on multiwalled carbon nanotubes/chitosan- modified carbon electrode
2021, Sensors and Actuators, B: ChemicalCitation Excerpt :The predominant alkaloids found in kratom leaves, contribute to the cross-reactivity of speciogynine and paynantheine [13]. Lee et al. [11] reported that, anti-mitragynine had high cross-reactivities with other closely related alkaloids in kratom including 7-hydroxymitragynine (83 %), paynantheine (54 %) and speciociliatine (63 %) and low percentage of cross reactivities with reserpine, morphine cocaine at less than 0.01 %. The result obtained was also in accordance to where the cross reactivities showed high percentage to the paynatheine and speciogynine due to their high similarity structure to the mitragynine [5], which possesses three stereocenters (3S, 15S and 20S), which potentially can cross-react with structurally-related compounds.
Clinical Pharmacology of the Dietary Supplement Kratom (Mitragyna speciosa)
2022, Journal of Clinical Pharmacology